Navigation Links
Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
Date:2/6/2008

EMERYVILLE, Calif., Feb. 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the BIO CEO & Investor Conference on Wednesday, February 13, at 11:00 a.m. Eastern Time. Interested parties may access a live webcast of the presentation at: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=ONXX&item_id=17524 28

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to listen to the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through March 13, 2008.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R) (sorafenib) tablets, a small molecule drug. Nexavar is currently approved for the treatment of advanced kidney cancer and for the treatment of liver cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer, and other tumor types. For more information about Onyx, visit the company's website at: http://www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
2. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
3. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
4. SGX Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
6. Memory Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
8. Celator(R) Pharmaceuticals to Present at 10th Annual BIO CEO and Investor Conference
9. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
10. Anthera Pharmaceuticals Forms Scientific Advisory Board
11. Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Feb. 16, 2017   Capricor Therapeutics, Inc. ... biotechnology company developing first-in-class biological therapies for cardiac ... has elected to terminate its license agreement with ... agonists, including Cenderitide. "Our decision to ... we prioritize our efforts to advance our core ...
(Date:2/16/2017)... UCHealth ( Aurora, Colorado ) ... nodule patient management. In addition to optimizing care coordination ... the lung, UCHealth looks to improve provider workflow by ... Stephanie Brown, RN , Thoracic Nurse Navigator, ... an Excel spreadsheet, which was extremely arduous and susceptible ...
(Date:2/16/2017)... ... February 16, 2017 , ... AxioMed ... Chin, professor and Harvard trained surgeon, completed the procedure on Monday, Jan. 30 ... 55-year-old practicing female physician suffering from degenerative disc disease with radiculomyelopathy, as a ...
(Date:2/16/2017)... NEW YORK , Feb. 16, 2017 ... $7M Series B financing, adding an additional $3M from ... by Mesa Verde Venture Partners and other strategic partners ... directed towards further accelerating commercial adoption of their flagship ... test and expanding the Paradigm cancer registry. ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 1, 2017  Central to its deep ... advances worldwide, The Japan Prize Foundation today announced ... have pushed the envelope in their respective fields ... Three scientists are being recognized with the 2017 ... not only contribute to the advancement of science ...
(Date:1/31/2017)... 31, 2017  Spero Therapeutics, LLC, a biopharmaceutical ... treatment of bacterial infections, today announced it has ... from Pro Bono Bio Ltd (PBB) to bolster ... resistant forms of Gram-negative bacteria.   The assets acquired ... a PBB group company. "The acquisition ...
(Date:1/26/2017)... , Jan. 26, 2017  Crossmatch, a leading ... a new solution aimed at combatting fraud, waste and ... was introduced at the Action on Disaster Relief conference ... meeting point for UN agencies and foreign assistance organizations ... Fraud, waste and abuse are a largely unacknowledged problem ...
Breaking Biology News(10 mins):